| abstract |
Described are embodiments related to gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) biomarkers and agents, systems, and kits for detecting the same, and associated GEP-NEN diagnostic, prognostic, and predictive methods and uses thereof, such as detection, prediction, staging, profiling, classification, and monitoring treatment efficacy and other outcomes. |